PDE9

Cyclic Nucleotide Phosphodiesterases in Health and Disease

Volumn , Issue , 2006, Pages 221-235

  Kotera, Jun ^a   Omori, Kenji ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77950279795     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (48)

1. Francis, S.H., and J.D. Corbin. 1999. Cyclic nucleotide-dependent protein kinases: Intracellular receptors for cAMP and cGMP action. Crit Rev Clin Lab Sci 36:275.
2. Beavo, J.A., and L.L. Brunton. 2002. Cyclic nucleotide research-still expanding after half a century. Nat Rev Mol Cell Biol 3:710.
3. Soderling, S.H., and J.A. Beavo. 2000. Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions. Curr Opin Cell Biol 12:174.
4. Beavo, J.A. 1995. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 75:725.
5. Francis, S.H., I.V. Turko, and J.D. Corbin. 2001. Cyclic nucleotide phosphodiesterases: Relating structure and function. Prog Nucleic Acid Res Mol Biol 65:1.
6. Aravind, L., and C.P. Ponting. 1997. The GAF domain: An evolutionary link between diverse phototransducing proteins. Trends Biochem Sci 22:458.
7. Yuasa, K., et al. 2001. Genomic organization of the human phosphodiesterase PDE11A gene: Evolutionary relatedness with other PDEs containing GAF domains. Eur J Biochem 268:168.
8. Fisher, D.A., et al. 1998. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 273:15559.
9. Soderling, S.H., S.J. Bayuga, and J.A. Beavo. 1998. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 273:15553.
10. Wunder, F., et al. 2005. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol Pharmacol 68:1775.
11. Aravind, L., and E.V. Koonin. 1998. The HD domain defines a new superfamily of metal-dependent phosphohydrolases. Trends Biochem Sci 23:469.
12. Andreeva, S.G., et al. 2001. Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain. J Neurosci 21:9068.
13. van Staveren, W.C., et al. 2002. Cloning and localization of the cGMP-specific phosphodiesterase type 9 in the rat brain. J Neurocytol 31:729.
14. Thomason, P.A., et al. 1998. An intersection of the cAMP/PKA and two-component signal transduction systems in Dictyostelium. EMBO J 17:2838.
15. Guipponi, M., et al. 1998. Identification and characterization of a novel cyclic nucleotide phosphodiesterase gene (PDE9A) that maps to 21q22.3: Alternative splicing of mRNA transcripts, genomic structure and sequence. Hum Genet 103:386.
16. Rentero, C., A. Monfort, and P. Puigdomenech. 2003. Identification and distribution of different mRNA variants produced by differential splicing in the human phosphodiesterase 9A gene. Biochem Biophys Res Commun 301:686.
17. Bonne-Tamir, B., et al. 1996. Linkage of congenital recessive deafness (gene DFNB10) to chromosome 21q22.3. Am J Hum Genet 58:1254.
18. Veske, A., et al. 1996. Autosomal recessive nonsyndromic deafness locus (DFNB8) maps on chromosome 21q22 in a large consanguineous kindred from Pakistan. Hum Mol Genet 5:165.
19. Straub, R.E., et al. 1994. A possible vulnerability locus for bipolar affective disorder on chromosome 21q22.3. Nat Genet 8:291.
20. Belmaker, R.H., J. Zohar, and R.P. Ebstein. 1980. Cyclic nucleotides in mental disorder. Adv Cyclic Nucleotide Res 12:187.
21. Ebstein, R.P., et al. 1988. Lithium modulation of second messenger signal amplification in man: Inhibition of phosphatidylinositol-specific phospholipase C and adenylate cyclase activity. Psychiatry Res 24:45.
22. Mathews, R., et al. 1997. Increased G alpha q/11 immunoreactivity in postmortem occipital cortex from patients with bipolar affective disorder. Biol Psychiatry 41:649.
23. Karlsson, J.O., et al. 1990. Cyclic guanosine monophosphate metabolism in human amnion cells trisomic for chromosome 21. Biol Neonate 57:343.
24. Antonarakis, S.E., et al. 2004. Chromosome 21 and Down syndrome: From genomics to pathophysiology. Nat Rev Genet 5:725.
25. Wang, P., et al. 2003. Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5). Differential tissue distribution and subcellular localization of PDE9A variants. Gene 314:15.
26. Huai, Q., et al. 2004. Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding. Proc Natl Acad Sci USA 101:9624.
27. Gbekor, E., et al. 2002. Selectivity of sildenafil and other phosphodiesterase type 5 (PDE5) inhibitors against all human phosphodiesterase families. Eur Urol 1 (Suppl 1):63.
28. Yanaka, N., et al. 1998. Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Eur J Biochem 255:391.
29. van Staveren, W.C., et al. 2003. mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J Comp Neurol 467:566.
30. van Staveren, W.C. and M. Markerink-van Ittersum. 2005. Localization of cyclic guanosine 3',5'-monophosphate-hydrolyzing phosphodiesterase type 9 in rat brain by nonradioactive in situ hybridization. Methods Mol Biol 307:75.
31. Kotera, J., et al. 1997. Expression of rat cGMP-binding cGMP-specific phosphodiesterase mRNA in Purkinje cell layers during postnatal neuronal development. Eur J Biochem 249:434.
32. Lupidi, G., et al. 1990. 3'-5' cAMP phosphodiesterase in pig liver nuclei. Ital J Biochem 39:30.
33. Lugnier, C., et al. 1999. Characterization of cyclic nucleotide phosphodiesterase isoforms associated to isolated cardiac nuclei. Biochim Biophys Acta 1472:431.
34. Benelli, C., et al. 1988. Changes in low-Km cAMP phosphodiesterase activity in liver Golgi fractions from hyper- and hypoinsulinemic rats. Diabetes 37:717.
35. Shakur, Y., et al. 1995. Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum. Biochem J 306:801.
36. Pooley, L., et al. 1997. Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines. Biochem J 321:177.
37. Jin, S.L., et al. 1998. Subcellular localization of rolipram-sensitive, cAMP-specific phosphodiesterases. Differential targeting and activation of the splicing variants derived from the PDE4D gene. J Biol Chem 273:19672.
38. Geoffroy, V., et al. 1999. Activation of a cGMP-stimulated cAMP phosphodiesterase by protein kinase C in a liver Golgi-endosomal fraction. Eur J Biochem 259:892.
39. Tasken, K.A., et al. 2001. Phosphodiesterase 4D and protein kinase a type II constitute a signaling unit in the centrosomal area. J Biol Chem 276:21999.
40. Dodge, K.L., et al. 2001. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO J 20:1921.
41. Verde, I., et al. 2001. Myomegalin is a novel protein of the Golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. J Biol Chem 276:11189.
42. Kotera, J., et al. 2004. Subcellular localization of cyclic nucleotide phosphodiesterase type 10A variants, and alteration of the localization by cAMP-dependent protein kinase-dependent phosphorylation. J Biol Chem 279:4366.
43. Asirvatham, A.L., et al. 2004. A-kinase anchoring proteins interact with phosphodiesterases in T lymphocyte cell lines. J Immunol 173:4806.
44. Yuasa, K., K. Omori, and N. Yanaka. 2000. Binding and phosphorylation of a novel male germ cell-specific cGMP-dependent protein kinase-anchoring protein by cGMP-dependent protein kinase Iα. J Biol Chem 275:4897.
45. Gudi, T., et al. 1996. Regulation of gene expression by cGMP-dependent protein kinase. Transactivation of the c-fos promoter. J Biol Chem 271:4597.
46. Chan, S.H., et al. 2004. Nitric oxide regulates c-fos expression in nucleus tractus solitarii induced by baroreceptor activation via cGMP-dependent protein kinase and cAMP response element-binding protein phosphorylation. Mol Pharmacol 65:319.
47. Wunder, F., et al. 2005. A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway. Anal Biochem 339:104.
48. Hendrix, M. 2005. Selective inhibitors of cGMP phosphodiesterases as procognitive agents. BMC Pharmacol 5 (Suppl 1):S5.